Skip to main content
Medic Debate
- The Antidote to Medical Misinformation and Propaganda!
Languages
Dansk
Nederlands
English
Français
Deutsch
Italiano
Español
Kiswahili
Svenska
Search form
Search
Main menu
Home
Search
About us
Books
Category Search
Log In
Recent posts
Treatment Protocols
You are here
Home
Bevacizumab
Items per page
5
10
20
40
60
100
Title
Average Rating
Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs.
90.00%
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients ....
80.00%
Bevacizumab for recurrent ependymoma.
80.00%
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
80.00%
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.
80.00%
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.
80.00%
Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm).
70.00%
Dose-Dense and/or Metronomic Schedules of Specific Chemotherapies Consolidate the Chemosensitivity of Triple-Negative Breast Can
63.33%
Hypoxia-inducible factor-1alpha modulation in combination with anti-angiogenic therapy.
60.00%
Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symp
60.00%
Anti-angiogenic therapies for metastatic colorectal cancer.
60.00%
Complete remission of psoriasis following bevacizumab therapy for colon cancer.
60.00%
Tumoral angiogenesis: review of the literature.
50.00%
Novel anti-angiogenic therapies for malignant gliomas.
50.00%
Chemoradiotherapy in malignant glioma: standard of care and future directions.
50.00%
Lessons learned in the development of targeted therapy for malignant gliomas
50.00%
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer.
50.00%
Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors.
50.00%
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal
50.00%
Circulating tumor and endothelial cells as pharmacodynamic biomarkers in a phase I clinical trial of intravenous bevacizumab....
40.00%
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplat
40.00%
A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer.